Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be Ex Vivo?

Developing a safe and efficacious vaccine that can induce broad and long-term immunity for SARS-CoV-2 infection is the most critical research to date. As the most potent APCs, dendritic cells (DCs) can induce a robust T cell immunity. In addition, DCs also play an essential role in COVID-19 pathogen...

Full description

Saved in:
Bibliographic Details
Published inExpert review of vaccines Vol. 21; no. 8; pp. 1111 - 1120
Main Authors Jonny, Jonny, Putranto, Terawan Agus, Sitepu, Enda Cindylosa, Irfon, Raoulian
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 03.08.2022
Subjects
Cell immunotherapy
COVID-19
dendritic cell
SARS-CoV-2
T cells
vaccination
COVID-19
SARS-CoV-2
T cells
dendritic cell
Cell immunotherapy
vaccination
Online AccessGet full text

Cover

More Information
Summary:Developing a safe and efficacious vaccine that can induce broad and long-term immunity for SARS-CoV-2 infection is the most critical research to date. As the most potent APCs, dendritic cells (DCs) can induce a robust T cell immunity. In addition, DCs also play an essential role in COVID-19 pathogenesis, making them a potential vaccination target. However, the DCs-based vaccine with ex vivo loading has not yet been explored for COVID-19. This review aims to provide the rationale for developing a DCs-based vaccine with ex vivo loading of SARS-CoV-2 antigen. Here, we discuss the role of DCs in immunity and the effect of SARS-CoV-2 infection on DCs. Then, we propose the mechanism of the DCs-based vaccine in inducing immunity and highlight the benefits of ex vivo loading of antigen. We make the case that an ex vivo loaded DC-based vaccination is appropriate for COVID-19 prevention.
ISSN:1476-0584
1744-8395
DOI:10.1080/14760584.2022.2080658